SLPライブシグナル | Getagraph.comで利益を最大化

売る 106365 min ago

@ $40.16

発行日: 15 2月 2024 @ 01:36

リターン: 11.29%

前回のシグナル: 2月 13 - 23:30

前回のシグナル: 買う

リターン: -0.88 %

Live Chart Being Loaded With Signals

Commentary (27 4月 2024 @ 05:00):

Stats
本日の出来高	76 473.00
平均出来高	109 138
時価総額	893.13M
EPS	$0 ( 2024-04-03 )
次の収益日	( $0.180 ) 2024-07-04
Last Dividend	$0.0600 ( 2023-10-27 )
Next Dividend	$0 ( N/A )
P/E	85.94
ATR14	$0.0440 (0.10%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	Woltosz Walter S	Sell	19 410	Common Stock
2024-04-01	Woltosz Walter S	Sell	590	Common Stock
2024-03-28	Szot Daniel	Buy	30 000	Stock Options (Right to Buy)
2024-03-01	Woltosz Walter S	Sell	17 600	Common Stock
2024-03-01	Woltosz Walter S	Sell	2 400	Common Stock

INSIDER POWER
-41.28
Last 97 transactions
Buy: 243 785 \| Sell: 655 613

ボリューム相関

長: 0.20 (neutral)

短: -0.48 (neutral)

Signal:(42.463) Neutral

Simulations Plus Inc 相関

10 最も正の相関
EMBCV	0.822

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Simulations Plus Inc 相関 - 通貨/商品

0.54
( weak )

0.25
( neutral )

0.00
( neutral )

0.70
( moderate )

-0.26
( neutral )

-0.81
( strong negative )

Simulations Plus Inc 財務諸表

Annual	2023
収益:	$59.58M
総利益:	$47.95M (80.48 %)
EPS:	$0.500

FY	2023
収益:	$59.58M
総利益:	$47.95M (80.48 %)
EPS:	$0.500

FY	2022
収益:	$53.91M
総利益:	$43.08M (79.92 %)
EPS:	$0.620

FY	2021
収益:	$46.47M
総利益:	$35.87M (77.19 %)
EPS:	$0.490

Financial Reports:

No articles found.

Simulations Plus Inc Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0.0600 (N/A)	$0.0600 (N/A)	$0.0600 (N/A)	$0.0600 (N/A)	$0.0600 (N/A)	$0.0600 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Simulations Plus Inc Dividend Information - Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 3.47 - Decrease likely (30.59%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.0500	2012-02-16
Last Dividend	$0.0600	2023-10-27
Next Dividend	$0	N/A
Payout Date	2023-11-06
Next Payout Date	N/A
# dividends	48	--
Total Paid Out	$2.69	--
Avg. Dividend % Per Year	0.37%	--
Score	4.4	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	3.47
Div. Directional Score	7.58	--

Next Divdend (Est)
(2024-07-09)

$0.0610 Estimate 39.78 %

Dividend Stability

0.80 Good

Dividend Score

4.40

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield
2012	$0.340	11.30%
2013	$0.100	2.29%
2014	$0.200	3.92%
2015	$0.200	2.95%
2016	$0.200	2.07%
2017	$0.210	2.33%
2018	$0.240	1.53%
2019	$0.240	1.21%
2020	$0.240	0.84%
2021	$0.240	0.32%
2022	$0.240	0.48%
2023	$0.240	0.65%
2024	$0	0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.163	1.500	6.75	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0542	1.200	8.19	9.83	[0 - 0.3]
returnOnEquityTTM	0.0611	1.500	-0.433	-0.649	[0.1 - 1]
payoutRatioTTM	0.455	-1.000	5.45	-5.45	[0 - 1]
currentRatioTTM	8.81	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	8.55	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	2.55	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.00532	-1.500	9.91	-10.00	[0 - 0.6]
interestCoverageTTM	6.31	1.000	8.77	8.77	[3 - 30]
operatingCashFlowPerShareTTM	0.880	2.00	9.71	10.00	[0 - 30]
freeCashFlowPerShareTTM	0.639	2.00	9.68	10.00	[0 - 20]
debtEquityRatioTTM	0.00583	-1.500	9.98	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.751	1.000	0.810	0.810	[0.2 - 0.8]
operatingProfitMarginTTM	0.171	1.000	8.57	8.57	[0.1 - 0.6]
cashFlowToDebtRatioTTM	17.03	1.000	10.00	10.00	[0.2 - 2]
assetTurnoverTTM	0.333	0.800	-1.111	-0.889	[0.5 - 2]
Total Score				11.69

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	84.89	1.000	1.526	0	[1 - 100]
returnOnEquityTTM	0.0611	2.50	-0.278	-0.649	[0.1 - 1.5]
freeCashFlowPerShareTTM	0.639	2.00	9.79	10.00	[0 - 30]
dividendYielPercentageTTM	0.537	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	0.880	2.00	9.71	10.00	[0 - 30]
payoutRatioTTM	0.455	1.500	5.45	-5.45	[0 - 1]
pegRatioTTM	-4.39	1.500	-10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.272	1.000	5.70	0	[0.1 - 0.5]
Total Score				3.47

Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through four segments: Simulations Plus, Cognigen, DILIsym, and Lixoft. The company offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. It also provides products based on mechanistic and mathematical models, such as DILIsym, a quantitative systems pharmacology software; NAFLDsym; IPFsym; RENAsym; and MITOsym. In addition, the company provides Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as modeling and simulation products comprising MonolixSuite and PKPlus. Further, it provides population modeling and simulation contract research services; training and consulting services designed to accelerate pharmacometrics studies; and clinical-pharmacology-based consulting services in support of regulatory submissions. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.